Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection.
James B DoubVincent Y NgMyounghee LeeAndrew ChiAlina LeeSilvia WürstleBenjamin ChanPublished in: Antibiotics (Basel, Switzerland) (2022)
Prosthetic joint infections are a devastating complication of joint replacement surgery. Consequently, novel therapeutics are needed to thwart the significant morbidity and enormous financial ramifications that are associated with conventional treatments. One such promising adjuvant therapeutic is bacteriophage therapy given its antibiofilm activity and its ability to self-replicate. Herein we discuss the case of a 70-year-old female who had a recalcitrant MRSA prosthetic knee and femoral lateral plate infection who was successfully treated with adjuvant bacteriophage therapy. Moreover, this case discusses the importance of propagating bacteriophage therapeutics on bacteria that are devoid of toxins and the need to ensure bacteriophage activity to all bacterial morphologies. Overall, this case reinforces the potential benefit of using personalized bacteriophage therapy for recalcitrant prosthetic joint infections, but more translational research is needed to thereby devise effective, reproducible clinical trials.
Keyphrases
- clinical trial
- minimally invasive
- early stage
- staphylococcus aureus
- methicillin resistant staphylococcus aureus
- small molecule
- total knee arthroplasty
- randomized controlled trial
- coronary artery disease
- mesenchymal stem cells
- acute coronary syndrome
- bone marrow
- coronary artery bypass
- health insurance
- phase ii
- placebo controlled